9 Things to Know About Urolithin A and Why Menopause Researchers Are Watching It
The fatigue and muscle softness that crept in around perimenopause felt completely disconnected from anything fixable — like the body was just slowly powering down. Learning that some of that might trace back to cellular energy machinery, and that there are compounds being studied specifically for this, made it feel less like an inevitable decline and more like a biology problem worth understanding.
Learn more about Rose →Urolithin A is a postbiotic, not a plant compound you eat directly
Urolithin A is produced in the gut when bacteria metabolize ellagitannins — polyphenols found in pomegranates, walnuts, and certain berries. The catch is that gut microbiome composition varies enormously between individuals, meaning some people produce useful amounts naturally while others produce very little regardless of diet. This is why researchers have been investigating supplemental urolithin A as a way to bypass the conversion bottleneck entirely.
Its primary mechanism is mitophagy — the cellular recycling of damaged mitochondria
Mitophagy is the process by which cells identify dysfunctional mitochondria and break them down so they can be replaced with healthier ones. Urolithin A has been shown in multiple studies to be one of the most potent naturally derived activators of this process. Without adequate mitophagy, damaged mitochondria accumulate, contributing to reduced cellular energy output — something that shows up in muscle, brain, and metabolic tissue.
Estrogen normally supports mitochondrial function — and its loss creates a specific vulnerability
Estrogen receptors are present on mitochondria in skeletal muscle, cardiac tissue, and the brain, where they help regulate mitochondrial biogenesis and efficiency. When estrogen declines during perimenopause, this protective signaling is reduced, and mitochondrial quality control can begin to slip. This is the biological context that makes urolithin A's mechanism particularly relevant to the menopausal transition — it may partially compensate for a pathway that estrogen was helping to maintain.
A landmark 2022 randomized controlled trial showed measurable improvements in muscle endurance
A double-blind RCT published in JAMA Network Open found that supplemental urolithin A (500mg daily for four months) significantly improved muscle endurance in middle-aged and older adults compared to placebo, as measured by hand grip and leg muscle fatigue tests. Mitochondrial gene expression markers also improved, suggesting the effect was genuinely cellular rather than incidental. The participant group included women in the relevant age range, though the trial was not menopause-specific.
It appears to improve mitochondrial gene expression even in people who already exercise
One of the more striking findings from urolithin A research is that its effects on mitochondrial biomarkers appear to be additive to exercise rather than simply mimicking it. This matters for perimenopausal and menopausal women who are already active but finding that their usual workouts are producing diminishing returns in terms of energy and muscle response. The biology suggests this isn't purely a motivation or effort problem — mitochondrial efficiency genuinely changes with estrogen loss.
Early research suggests it may support skeletal muscle preservation specifically — not just general energy
Sarcopenia, the age-related loss of skeletal muscle mass and strength, accelerates significantly after menopause due to both estrogen withdrawal and declining anabolic signaling. Urolithin A has shown preclinical and early clinical signals of benefit specifically in skeletal muscle tissue, which has a high density of mitochondria and is especially sensitive to mitochondrial dysfunction. Researchers are now designing trials that target postmenopausal women as a primary population rather than a subgroup.
Its safety profile in humans looks reassuring so far, but long-term data is still limited
Phase 1 and Phase 2 clinical trials have found urolithin A to be well-tolerated at doses up to 1000mg per day with no serious adverse events reported. Short-term biomarker studies have shown no concerning signals in liver, kidney, or cardiovascular markers. However, the longest trials to date run only four to six months, so genuinely long-term safety data — particularly in populations using hormone therapy simultaneously — does not yet exist.
There is emerging, preliminary research connecting urolithin A to cognitive and neurological energy metabolism
Mitochondrial dysfunction in brain tissue is increasingly implicated in cognitive aging and conditions like brain fog, which is frequently reported during the menopausal transition. Animal and early in vitro studies suggest urolithin A can cross the blood-brain barrier and activate mitophagy in neural tissue, though human cognitive outcome trials are not yet complete. This is a genuinely early signal, not a proven benefit — but it explains why neuroscience researchers have joined the conversation alongside muscle physiologists.
Urolithin A is not a replacement for hormone therapy, resistance training, or foundational nutrition
The research positioning urolithin A as a mitophagy activator places it squarely in the category of cellular support — not a hormonal intervention and not a substitute for the lifestyle factors that most powerfully influence muscle and metabolic health during menopause. The women showing the best outcomes in longevity and muscle research consistently combine resistance training, adequate protein intake, and — where appropriate and accessible — hormone therapy. Urolithin A, if it proves out, is likely to be most useful as a complement to those foundations, not a shortcut around them.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.